Menotrophin

Menotrophin contains both follicle‑stimulating hormone (FSH) and luteinising hormone (LH) analogues. These bind to FSH and LH receptors on ovarian granulosa and theca cells, stimulating follicular growth, estradiol synthesis and final maturation, ultimately leading to ovulation.

The prescribed dose of Menotrophin is individualized by the treating physician based on the patient’s ovarian response, age, body weight and the specific assisted reproduction protocol. Dosing regimens are determined after baseline assessment and monitoring.

Menotrophin is intended for use before conception to induce ovulation; it is not administered during an established pregnancy. Safety data for use while breastfeeding are limited, and the product should be avoided unless the prescriber determines that benefits outweigh potential risks.

To place an order, submit an enquiry on the Menotrophin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with recombinant FSH preparations, Menotrophin provides a combination of FSH and LH activity in a single preparation, which can simplify dosing for patients requiring both hormones. Recombinant products are pure FSH and may be preferred when isolated LH activity is not needed. Clinical choice depends on protocol, cost, and patient response.

Menotrophin must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. If the product reaches room temperature, it should be returned to refrigeration promptly and used within the stability period indicated by the manufacturer.

Menotrophin is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. The injection is typically performed by a trained healthcare professional or a patient after proper instruction. Injection sites are rotated to minimize local reactions, and dosing is adjusted according to ultrasound monitoring of follicular development.

The most serious adverse events include severe ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, fluid accumulation, and thromboembolic complications, as well as multiple pregnancy and rare allergic reactions such as anaphylaxis. Prompt medical evaluation is required if any of these symptoms occur.

Menotrophin is contraindicated in women with known hypersensitivity to any component of the product, in those with active ovarian cysts, uncontrolled thyroid disease, hormone‑dependent tumors, or in pregnancy. Caution is advised for patients with severe cardiovascular disease or a history of thromboembolic events. The prescribing clinician determines suitability.